- Home
- CMMB vs QCLS Comparison
CMMB vs QCLS Comparison
Compare CMMB & QCLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- QCLS
- Stock Information
- Founded
- CMMB 2004
- QCLS 2014
- Country
- CMMB Israel
- QCLS United States
- Employees
- CMMB N/A
- QCLS N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- QCLS Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CMMB Health Care
- QCLS Health Care
- Exchange
- CMMB Nasdaq
- QCLS Nasdaq
- Market Cap
- CMMB 13.8M
- QCLS 12.5M
- IPO Year
- CMMB N/A
- QCLS N/A
- Fundamental
- Price
- CMMB $2.54
- QCLS $3.72
- Analyst Decision
- CMMB Strong Buy
- QCLS
- Analyst Count
- CMMB 2
- QCLS 0
- Target Price
- CMMB $26.50
- QCLS N/A
- AVG Volume (30 Days)
- CMMB 80.5K
- QCLS 812.5K
- Earning Date
- CMMB 11-20-2025
- QCLS 11-19-2025
- Dividend Yield
- CMMB N/A
- QCLS N/A
- EPS Growth
- CMMB N/A
- QCLS N/A
- EPS
- CMMB N/A
- QCLS N/A
- Revenue
- CMMB N/A
- QCLS N/A
- Revenue This Year
- CMMB N/A
- QCLS N/A
- Revenue Next Year
- CMMB N/A
- QCLS N/A
- P/E Ratio
- CMMB N/A
- QCLS N/A
- Revenue Growth
- CMMB N/A
- QCLS N/A
- 52 Week Low
- CMMB $2.36
- QCLS $2.50
- 52 Week High
- CMMB $9.84
- QCLS $164.00
- Technical
- Relative Strength Index (RSI)
- CMMB 42.45
- QCLS N/A
- Support Level
- CMMB $2.36
- QCLS N/A
- Resistance Level
- CMMB $2.85
- QCLS N/A
- Average True Range (ATR)
- CMMB 0.20
- QCLS 0.00
- MACD
- CMMB -0.02
- QCLS 0.00
- Stochastic Oscillator
- CMMB 32.71
- QCLS 0.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About QCLS Q/C Technologies Inc. Common Stock
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.